AbbVie reports positive findings from rheumatoid arthritis drug trial

AbbVie has announced positive top-line results from a phase III clinical trial assessing the investigational therapy upadacitinib in the treatment of rheumatoid arthritis.

The oral JAK1-selective inhibitor showed a strong safety and efficacy performance when used among patients with moderate to severe rheumatoid arthritis who had not adequately responded to treatment with conventional synthetic DMARD therapies.

After 12 weeks of treatment in the SELECT-NEXT study, both the 15 mg and 30 mg doses of upadacitinib met the study's primary endpoints, with nearly half of patients achieving low disease activity and around 30 percent achieving clinical remission.

These findings come as part of the broader SELECT phase III study programme, which is evaluating the drug among more than 4,000 patients with moderate to severe rheumatoid arthritis across six studies.

Dr Michael Severino, executive vice-president for research and development and chief scientific officer at AbbVie, said: "AbbVie's longstanding leadership in the treatment of immune-mediated diseases provides an opportunity to build upon our understanding and develop innovative therapies to address unmet patient needs."

Upadacitinib is being assessed across several immune-mediated conditions, including psoriatic arthritis, Crohn's disease, ulcerative colitis and atopic dermatitis.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.